Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 42

1.

Functional brain imaging of cognitive dysfunction in Parkinson's disease.

Hirano S, Shinotoh H, Eidelberg D.

J Neurol Neurosurg Psychiatry. 2012 Oct;83(10):963-9. doi: 10.1136/jnnp-2011-301818. Epub 2012 Jul 17. Review.

PMID:
22807560
2.

Radionuclide brain imaging correlates of cognitive impairment in Parkinson's disease (PD).

Nobili F, Morbelli S, Arnaldi D, Ferrara M, Campus C, Brugnolo A, Mazzei D, Mehrdad N, Sambuceti G, Rodriguez G.

J Neurol Sci. 2011 Nov 15;310(1-2):31-5. doi: 10.1016/j.jns.2011.06.053. Epub 2011 Jul 16. Review.

PMID:
21762928
3.

Prefrontal dopamine signaling and cognitive symptoms of Parkinson's disease.

Narayanan NS, Rodnitzky RL, Uc EY.

Rev Neurosci. 2013;24(3):267-78. doi: 10.1515/revneuro-2013-0004. Review.

4.

A convergent model for cognitive dysfunctions in Parkinson's disease: the critical dopamine-acetylcholine synaptic balance.

Calabresi P, Picconi B, Parnetti L, Di Filippo M.

Lancet Neurol. 2006 Nov;5(11):974-83. Review.

PMID:
17052664
5.

Amyloid PET Imaging in Lewy body disorders.

Donaghy P, Thomas AJ, O'Brien JT.

Am J Geriatr Psychiatry. 2015 Jan;23(1):23-37. doi: 10.1016/j.jagp.2013.03.001. Epub 2013 Jul 3. Review.

PMID:
23831180
6.

Cognitive impairment in degenerative parkinsonisms: role of radionuclide brain imaging.

Arnaldi D, Morbelli S, Morrone E, Campus C, Nobili F.

Q J Nucl Med Mol Imaging. 2012 Feb;56(1):55-67. Review.

PMID:
22460160
7.

Imaging amyloid in Parkinson's disease dementia and dementia with Lewy bodies with positron emission tomography.

Brooks DJ.

Mov Disord. 2009;24 Suppl 2:S742-7. doi: 10.1002/mds.22581. Review.

PMID:
19877240
8.

Functional imaging of cognitive impairment in Parkinson's disease.

Fitzpatrick T, Mattis P, Eidelberg D.

Clin EEG Neurosci. 2010 Jul;41(3):119-26. Review.

PMID:
20722344
9.

Cholinesterase inhibitors for dementia with Lewy bodies, Parkinson's disease dementia and cognitive impairment in Parkinson's disease.

Rolinski M, Fox C, Maidment I, McShane R.

Cochrane Database Syst Rev. 2012 Mar 14;(3):CD006504. doi: 10.1002/14651858.CD006504.pub2. Review.

PMID:
22419314
10.

[Cognitive impairment in Parkinson's disease].

Tachibana H.

Seishin Shinkeigaku Zasshi. 2013;115(11):1142-9. Review. Japanese.

PMID:
24450147
11.

[Parkinson syndrome and cognitive disorders].

Szirmai I, Kovács T.

Ideggyogy Sz. 2002 Jul 20;55(7-8):220-5. Review. Hungarian.

PMID:
12201229
12.

Effects of the adenosine A2A receptor antagonist on cognitive dysfunction in Parkinson's disease.

Uchida S, Kadowaki-Horita T, Kanda T.

Int Rev Neurobiol. 2014;119:169-89. doi: 10.1016/B978-0-12-801022-8.00008-8. Review.

PMID:
25175966
14.

Cognitive and behavioral dysfunction in Parkinson's disease: neurochemical and clinicopathological contributions.

Zgaljardic DJ, Foldi NS, Borod JC.

J Neural Transm (Vienna). 2004 Oct;111(10-11):1287-301. Epub 2004 Jul 7. Review.

PMID:
15480839
15.

Amyloid deposition in Parkinson's disease and cognitive impairment: a systematic review.

Petrou M, Dwamena BA, Foerster BR, MacEachern MP, Bohnen NI, Müller ML, Albin RL, Frey KA.

Mov Disord. 2015 Jun;30(7):928-35. doi: 10.1002/mds.26191. Epub 2015 Apr 16. Review.

16.

Functional imaging of cognition in Parkinson's disease.

Carbon M, Marié RM.

Curr Opin Neurol. 2003 Aug;16(4):475-80. Review.

PMID:
12869806
17.

Early involvement of the cerebral cortex in Parkinson's disease: convergence of multiple metabolic defects.

Ferrer I.

Prog Neurobiol. 2009 Jun;88(2):89-103. doi: 10.1016/j.pneurobio.2009.02.004. Epub 2009 Mar 9. Review.

PMID:
19482226
18.

Imaging the nigrostriatal system to monitor disease progression and treatment-induced complications.

Kuriakose R, Stoessl AJ.

Prog Brain Res. 2010;184:177-92. doi: 10.1016/S0079-6123(10)84009-9. Review.

PMID:
20887875
19.

Update on SPECT and PET in parkinsonism - part 2: biomarker imaging of cognitive impairment in Lewy-body diseases.

Meyer PT, Frings L, Hellwig S.

Curr Opin Neurol. 2014 Aug;27(4):398-404. doi: 10.1097/WCO.0000000000000107. Review.

PMID:
24978635
20.

Neuropharmacological treatment of mental dysfunction in Parkinson's disease.

McNamara P, Durso R.

Behav Neurol. 2006;17(1):43-51. Review.

Supplemental Content

Support Center